What Cohance does
Founded in 2018, Cohance operates in the Health Tech sector offering an integrated, technology-driven global CDMO platform committed to advancing therapeutics for a healthier world. The company, rebranded from Suven Pharmaceuticals, focuses on collaboration and innovation to enhance molecular development. Cohance aims to support global innovators by providing transformative solutions to patients and consumers. The rebranding reflects a sharpened vision aligned with their mission to drive advancements in healthcare.
Funding and finances
Why this matters to you: funding stage is a rough proxy for how long the runway is and how much structure to expect. It is not a promise, and a profitable bootstrapped company can be the safer bet.
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about Cohance yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.